On July 17, Guardant Health fell 5.02% in regular trading, trading at $154.86 USD/share, with Turnover of $3.59 billion.
Within the Health Care Services sector where Guardant Health belongs, performance was mixed. Among individual stocks, Quest Diagnostics up 3.79%, CVS Health up 0.55%, BrightSpring Health Services down 0.12%, THE CIGNA GROUP down 5.05%, Hims & Hers Health down 9.46%.
Guardant Health is a leading precision oncology company that provides blood and tissue tests, data sets, and analytics. Its product portfolio includes Guardant360, Guardant360 CDx, Shield Test, and Guardant Reveal, covering advanced-stage cancer genomic profiling, early cancer screening, and therapy response monitoring. The company's next earnings report is scheduled for July 30 after market close.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments